Nasolacrimal drainage system implants for drug therapy
An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.
1. A drug delivery system for insertion into a lacrimal canaliculus of a patient, comprising:
a drug supply matrix comprising a therapeutic agent and a hydrogel polymer comprising polyethylene oxide, wherein the drug supply matrix is a cylindrical rod.
2. The drug delivery system of claim 1 , wherein the system does not comprise a sheath body.
3. The drug delivery system of claim 1 , wherein the therapeutic agent is selected from an anti-glaucoma agent, a corticosteroid, an anti-microbial agent, an anti-allergy agent or a non-steroidal anti-inflammatory agent.
4. The drug delivery system of claim 1 , wherein the therapeutic agent is selected from latanoprost, bimatoprost, travoprost, timolol maleate, cyclosporine, dexamethasone or non-steroidal anti-inflammatories.
5. The drug delivery system of claim 1 , wherein the system is used to treat glaucoma, pre and post surgical treatments, dry eye or allergy.
6. The drug delivery system of claim 1 , wherein the therapeutic agent is dexamethasone.
7. The drug delivery system of claim 1 , wherein the therapeutic agent is an antibiotic or antifungal agent.
8. The drug delivery system of claim 1 , wherein the therapeutic agent is a prostaglandin, a prostaglandin precursor, a beta-blocker, or a prostaglandin analog.
9. The drug delivery system of claim 1 , wherein the therapeutic agent is travoprost.
10. The drug delivery system of claim 1 , wherein the hydrogel swells when the system is inserted into the lacrimal canaliculus of a patient.
11. The drug delivery system of claim 1 , wherein the matrix comprises biodegradable polymers.
12. A drug delivery system for insertion into a lacrimal canaliculus of a patient, comprising:
a drug supply matrix comprising a therapeutic agent and a hydrogel polymer comprising polyethylene oxide, wherein the therapeutic agent is selected from an anti-glaucoma agent, a corticosteroid an anti-microbial agent, an anti-allergy agent or a non-steroidal anti-inflammatory agent, and wherein the drug supply matrix is a cylindrical rod.
13. The drug delivery system of claim 12 , wherein the system does not comprise a sheath body.
14. The drug delivery system of claim 12 , wherein the therapeutic agent is selected from latanoprost, bimatoprost, travoprost, timolol maleate, cyclosporine, or dexamethasone.
15. The drug delivery system of claim 12 , wherein the system is used to treat glaucoma, pre and post surgical treatments, dry eye or allergy.
16. The drug delivery system of claim 12 , wherein the therapeutic agent is dexamethasone.
17. The drug delivery system of claim 12 , wherein the therapeutic agent is a prostaglandin, a prostaglandin precursor, a beta-blocker, or a prostaglandin analog.
18. The drug delivery system of claim 12 , wherein the therapeutic agent is travoprost.
19. The drug delivery system of claim 12 , wherein the hydrogel swells when the system is inserted into the lacrimal canaliculus of a patient.
20. The drug delivery system of claim 12 , wherein the matrix comprises biodegradable polymers.